EPIDUO Drug Patent Profile

Which patents cover Epiduo, and when can generic versions of Epiduo launch?

Epiduo is a drug marketed by Galderma Labs Lp and Galderma Labs and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-five patent family members in twenty-two countries.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epiduo

A generic version of EPIDUO was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for EPIDUO

International Patents:	35
US Patents:	3
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	31
Patent Applications:	66
Drug Prices:	Drug price information for EPIDUO
Drug Sales Revenues:	Drug sales revenues for EPIDUO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDUO
What excipients (inactive ingredients) are in EPIDUO?	EPIDUO excipients list
DailyMed Link:	EPIDUO at DailyMed

See drug prices for EPIDUO

See drug sales revenues for EPIDUO

Recent Clinical Trials for EPIDUO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	Phase 2
Beiersdorf	Phase 2
Mahidol University	Phase 2

See all EPIDUO clinical trials

Pharmacology for EPIDUO

Drug Class

Retinoid

Paragraph IV (Patent) Challenges for EPIDUO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO	Gel	adapalene; benzoyl peroxide	0.1%/2.5%	022320	1	2011-12-30

US Patents and Regulatory Information for EPIDUO

EPIDUO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	AB	RX	Yes	Yes
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes			Y

Expired US Patents for EPIDUO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008

International Patents for EPIDUO

When does loss-of-exclusivity occur for EPIDUO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

France

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008246274
Poland	2046318
Hungary	E025484
Hungary	230439	Legalább egy retinoidot és benzoil-peroxidot tartalmazó gél (Gel comprising at least a retinoid and benzoyl peroxide)
Japan	2009542779
Slovenia	2046318
China	101541320

Supplementary Protection Certificates for EPIDUO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
0199636	300209	Netherlands		300209, 20060411, EXPIRES: 20070702
1458369	122008000041	Germany		PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
1458369	08C0024	France		PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618
1458369	380	Finland
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111

EPIDUO Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

EPIDUO is a prescription topical dermatology product line marketed for acne: adapalene 0.1% / benzoyl peroxide 2.5% (fixed-dose gel). From a market-dynamics and financial-trajectory standpoint, its outlook is shaped by four forces: (1) steady prevalence of acne care, (2) intensifying generic competition against brand compositions and the broader topical acne category, (3) payer and channel migration toward cost-effective generics and formularies, and (4) supply and product-cycle effects tied to regulatory approvals, labeling, and commercialization geography.

What is EPIDUO’s product position in acne therapy?

EPIDUO is a fixed-dose combination topical that targets multiple acne pathways. In practice, the product sits inside a crowded topical acne landscape that includes:

• Topical retinoids (adapted to acne inflammatory and comedonal pathways)
• Benzoyl peroxide products (anti-bacterial / anti-inflammatory)
• Fixed-dose combinations (retinoid + benzoyl peroxide)
• Other combination regimens (retinoid + antibiotic combinations in some markets)
• Procedural and systemic acne treatments (topical-only share is pressured by escalation)

Key commercial implication: EPIDUO competes not only against “other brands” but against all cost tiers in the topical acne market, including generics that can displace combination branded products once exclusivity gaps close.

How do pricing, reimbursement, and formularies typically move for EPIDUO?

EPIDUO’s financial trajectory is largely determined by how health technology assessment and payer formularies respond to:

• Generic availability of adapalene/benzoyl peroxide combinations or interchangeable single-ingredient products
• Therapeutic equivalence assumptions (often based on comparable active ingredients and dosing forms)
• Patient adherence economics (fixed-dose combinations can win versus multi-step regimens, but cost still dominates once generics are available)

In mature dermatology categories, brand topical products tend to experience:

• Net price erosion after formulary penetration of lower-cost alternatives
• Higher rebate pressure to defend placements
• Shift in segment mix from commercial to managed care lines as formularies tighten

For EPIDUO specifically, the commercial “center of gravity” usually shifts from brand-premium patients to payer-driven switching to lower-cost options over the product lifecycle.

What drives demand in acne for a fixed-dose topical like EPIDUO?

Demand for EPIDUO is anchored to acne epidemiology and care patterns, but the day-to-day commercial outcome hinges on adoption and persistence:

Growth drivers

• Large treatable population and ongoing dermatologist and primary-care diagnosis
• Clinician preference for combination therapy when efficacy and adherence are considered
• Patient convenience of a single fixed-dose regimen versus separate retinoid and peroxide products

Dampers

• Irritation and tolerability that can reduce persistence
• Seasonality (some markets see adherence dips in high-irritant seasons or due to skin sensitivity)
• Switching behavior once lower-cost fixed-dose or equivalent regimens are available

Business impact: EPIDUO’s sales path typically tracks dermatology prescribing plus refill persistence, which is sensitive to tolerability and payer cost pressure.

How does generic and competitive intensity affect EPIDUO’s market share over time?

Topical acne is one of the more defensible areas for brands early in lifecycle because combination regimens can reduce patient burden. Over time, however, competitiveness increases through:

• Generics of the same actives in similar strengths
• “Same-ingredient switching” from combination gels to single-ingredient retinoids plus benzoyl peroxide
• Alternative branded combinations in certain geographies
• Brand consolidation and portfolio rationalization by originators

Commercial pattern in dermatology: branded fixed-dose products typically maintain share longer than single-agent products only if (a) formulation differentiators persist, (b) payers value adherence and persistence, and (c) the price premium is tolerable. Otherwise, the category moves quickly to least-cost clinically acceptable options.

What is the likely financial trajectory for EPIDUO sales?

EPIDUO’s financial trajectory is best understood as a lifecycle curve shaped by the timing of:

• Initial market authorizations and uptake
• Peak brand penetration across major markets
• Onset of generic competition for adapalene/benzoyl peroxide combinations or equivalents
• Subsequent share and pricing actions through rebates and formulary positioning

In mature topical products, the typical trajectory is:

1. Early adoption and scaling after launch and prescriber education
2. Stabilization when brand is broadly listed
3. Gradual decline as lower-cost alternatives expand formulary share
4. Volatility tied to competitive entry waves, product discontinuations, and label refinements

What this means for investors and planners: EPIDUO’s near-to-midterm revenue should be modeled more like a defensive, erosion-managed asset than a growth engine, with upside only where brand-to-generic switching is blocked by formulary design, patient persistence advantages, or differentiated formulation/regimen economics.

Which markets and regulatory events shape EPIDUO’s revenue outlook?

EPIDUO is marketed by different entities by geography and is supported by regulatory approvals that typically include age indications and acne severity positioning.

Two operational facts matter for revenue modeling:

• Regulatory status gates access and drives the speed of generic entry
• Indication wording and labeling constraints can affect substitution behavior

However, the commercial trajectory across markets still converges on the same economics: once generic equivalents arrive and formularies adopt interchangeability, net sales tend to decline unless the brand offsets with contracting, differentiated channels, or additional value levers.

What are the cash-flow and earnings sensitivities for EPIDUO?

For an established topical brand like EPIDUO, key financial sensitivities include:

• Net price and rebate rate changes driven by payer negotiations and competitive entry
• Volume shift from higher-tier to lower-tier reimbursement bands
• Marketing and detailing costs required to maintain persistence versus lower-cost switching
• Gross-to-net compression as competitive intensity rises
• Shelf availability and distribution economics affecting prescription fill rates

Because EPIDUO’s competitive set is largely substitution-ready, gross margin tends to be pressured by channel pricing. The dominant lever becomes defending net revenue per prescription rather than expanding the number of prescriptions without cost investment.

How should EPIDUO be benchmarked versus the topical acne competitive set?

A practical benchmarking approach for EPIDUO’s financial trajectory uses category-level dynamics:

Comparable product logic

• Fixed-dose topical acne combinations with overlapping active ingredients
• Comparable prescription-only dermatology channels (dermatology and primary care)
• Similar patient education and adherence considerations

Expected cross-effects

• If combination therapy is clinically favored, EPIDUO can hold share longer than single-agent products
• If payer prioritizes cost containment, EPIDUO loses share to generics faster than multi-active brands with higher differentiation

What business scenarios are most relevant for EPIDUO planning?

For modeling and portfolio decision-making, the scenario set usually reduces to two dominant paths:

1. Managed erosion scenario: EPIDUO loses incremental share to generics but remains listed, with net price decline offset by persistence and continued prescribing. Revenue declines, but cash flow stays serviceable.
2. Accelerated displacement scenario: rapid generic switching plus formulary moves push prescriptions toward least-cost regimens. Revenue declines faster, leading to sharper gross-to-net pressure and potential margin compression.

The determining factor is payer behavior around fixed-dose combinations versus separate-ingredient regimens, and the speed and breadth of generic substitution.

Key Takeaways

• EPIDUO is a fixed-dose adapalene/benzoyl peroxide topical acne product whose financial performance is driven by lifecycle economics typical of topical dermatology.
• Market dynamics favor least-cost substitution over time, so generic and formulary pressure is the primary driver of sales erosion.
• The near-to-midterm trajectory should be modeled as managed decline, with upside only if EPIDUO retains formulary positioning and persistence advantages.
• Financial sensitivity centers on net pricing, rebate rates, and prescription volume under substitution pressure, not on category growth alone.

FAQs

1. Is EPIDUO primarily competing with other fixed-dose acne combinations or with single-ingredient products?
   Both. In payer-driven channels, it competes against fixed-dose equivalents and also against separate retinoid plus benzoyl peroxide regimens that become least-cost options.

2. What most influences EPIDUO persistence and refill behavior?
   Skin tolerability, irritation profile, and regimen simplicity. Persistence tends to weaken when irritation reduces adherence.

3. What is the main driver of EPIDUO net revenue deterioration?
   Gross-to-net compression driven by rebate escalation and price erosion after generic entrants gain formulary traction.

4. Does acne category growth automatically translate to EPIDUO growth?
   Not reliably. Growth in treated population can be offset by switching toward generics and cost-optimized alternatives in managed care.

5. How should EPIDUO be valued in an investment or R&D portfolio context?
   As a defensive, lifecycle-erosion asset where value depends on duration of formulary defense, pricing power through rebates, and persistence relative to interchangeable options.

References

[1] EMA. EPIDUO (adapalene/benzoyl peroxide) product information and summaries where applicable. European Medicines Agency.
[2] FDA. Drug products and labeling references for adapalene and benzoyl peroxide combinations relevant to topical acne therapy. U.S. Food and Drug Administration.
[3] PubChem. Adapalene and benzoyl peroxide compound profiles and related data. National Library of Medicine, NCBI.
[4] NICE. Acne vulgaris: management guidance relevant to topical combination therapy positioning (where applicable). National Institute for Health and Care Excellence.